Article: Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings.

Trial Demonstrates Safety and Preliminary Efficacy and Supports Further Clinical Development of tgAAC94

BOSTON and SEATTLE, May 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation issued a news release earlier today, entitled "Targeted Genetics Reports Additional Data From Inflammatory Arthritis Clinical Trial," announcing additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin Anklesaria, Ph.D., vice president of therapeutic development for Targeted Genetics, presented the data in an oral presentation at the 11th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

To clarify, ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!